Drug Trial Radar · NCT03719313
Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
Last checked: Nov 19, 2026Latest source record: Apr 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
407
Actual
Start
Dec 1, 2018
Primary completion
Oct 6, 2022
Study completion Mar 24, 2023
Sponsor
- Lead sponsor
- Eiger BioPharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 25, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two LNF-containing regimens will be evaluated in the D-LIVR Phase 3 study: (1) LNF/RTV/PEG IFN-alfa-2a and (2) LNF/RTV. Each of these arms will have efficacy endpoints that measure clinical benefit with regard to viral suppression and alanine aminotransferase (ALT) normalization. For each LNF-containing regimen, a composite endpoint of EOT (48 weeks) virologic response and ALT normalization will be used. Virologic response will be defined as a 2 log10 IU/mL reduction from baseline.
Conditions
- Hepatitis Delta Virus
Interventions
LonafarnibDrug
Lonafarnib (LNF) 50 mg BID
RitonavirDrug
Ritonavir (RTV) 100 mg BID
PEG IFN-alfa-2aDrug
PEG IFN alfa-2a 180 mcg QW
Placebo LonafarnibDrug
Placebo
Placebo RitonavirDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the composite virologic and biochemical response rate at end-of-treatment (EOT) in patients who receive LNF 50 mg/RTV 100 mg BID vs patients who receive placebo.Time frame: 48 weeks
- To compare the composite virologic and biochemical response rate at EOT in patients who receive LNF 50 mg/RTV 100 mg BID with PEG IFN-alfa-2a 180 mcg QW vs patients who receive placebo.Time frame: 48 weeks
Locations
116 sites in 22 countries. Site status is shown where the registry gives one.
UCSF Fresno
Fresno, California
Ruane Clinical Research Group Inc.
Los Angeles, California
Asia Pacific Liver Center
Los Angeles, California
Stanford University
Palo Alto, California
University of California Davis Health System
Sacramento, California
Kaiser Permanente Medical Center Sacramento
Sacramento, California
Yale University Medical Center
New Haven, Connecticut
University of Miami Schiff Center for Liver Disease
Miami, Florida
Rush University Medical Center
Chicago, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
National Institutes of Health
Bethesda, Maryland
Henry Ford Health System
Detroit, Michigan
Mt. Sinai Hospital
New York, New York
NYU Langone Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Central Sooner Research
Norman, Oklahoma
University of Texas Southwestern Medical Center
Dallas, Texas
Baylor St. Luke's Medical Center
Houston, Texas
ZNA Stuivenberg
Antwerp, Belgium
C.H.U. Brugmann
Brussels, Belgium
Cliniques Universitaires de Bruxelles Hopital Erasme
Brussels, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
CHU Sart Tilman
Liège, Belgium
Acibadem City Clinic Tokuda Hospital Ead
Sofia, Bulgaria
UMHAT "Alexandrovska" EAD
Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", EAD
Sofia, Bulgaria
Medical Center "Nov Rehabilitatsionen Tsentar", EOOD
Stara Zagora, Bulgaria
University of Calgary
Calgary, Alberta, Canada
University Health Network
Toronto, Ontario, Canada
Toronto Liver Centre
Toronto, Ontario, Canada
McGill University Health Centre/Glen Site / Royal Victoria Hospital
Montreal, Quebec, Canada
CHU Nice - Hôpital de l'Archet 2
Nice, Alpes Maritimes, France
CHU Strasbourg - Hôpital Hautepierre
Strasbourg, Bas Rhin, France
CHU Bordeaux - Hôpital Haut-Lévêque
Pessac, Gironde, France
Hôpital Beaujon
Clichy, Hauts De Seine, France
CHU de Grenoble - Hôpital Nord
La Tronche, Isere, France
Centre Hospitalier de la Croix Rousse
Lyon, Rhone, France
Hôpital Jean Verdier
Bondy, Seine Saint Denis, France
Hôpital Paul Brousse
Villejuif, Val De Marne, France
Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH
Berlin, Germany
Showing 40 of 116 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.